Markets

Late-stage eye disease biotech Ocular Therapeutix sets terms for $75 million IPO

Ocular Therapeutix, which develops and markets eye therapeutics using its sustained-release hydrogel platform, announced terms for its IPO on Friday. The Bedford, MA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, it would command a fully diluted market value of $325 million.

Ocular Therapeutix, which was founded in 2006, plans to list on the NASDAQ under the symbol OCUL. One of the company's products was approved in January and Ocular booked $27,000 in sales for the three months ended March 31, 2014. Morgan Stanley, Cowen & Company and RBC Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of July 21, 2014.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

OCUL

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More